MetaCap

Precision BioSciences (DTIL) vs TRex Bio (TRXB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TRex Bio is the larger company by market cap ($297.0 million vs $282.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DTIL+10.12%TRXB-26.32%
+62%+12%-37%
Oct 9, 20261 yearNov 20, 2026
DTIL+10.12%TRXB-26.32%
+62%+16%-31%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DTIL versus TRXB key metrics
MetricDTILTRXB
Share price$7.40$10.32
Market cap$282.46M$296.95M
1-day change+7.09%+6.12%
YTD return+77.88%—
1-year return+48.00%—
5-year return-97.23%—
P/E ratio (TTM)29.60—
EPS (TTM)$0.25$-2.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$34.26M—
Revenue growth (YoY)-50.12%—
Net income (latest FY)$-45.72M—
Operating margin-152.19%—
Net margin-133.45%—
52-week high$11.29$16.56
52-week low$3.53$9.06
Distance from 52-week high-34.46%-37.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+297.30%+183.57%
Average volume319.79K156.80K
Shares outstanding38.17M28.79M
Employees6960
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Precision BioSciences

DTIL stock →

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees

About TRex Bio

TRXB stock →

TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

DTIL vs TRXB FAQ

Which is bigger, Precision BioSciences or TRex Bio?

TRex Bio (TRXB) is larger, with a market capitalization of $296.95M compared with $282.46M for Precision BioSciences (DTIL).

Are Precision BioSciences and TRex Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons